The intraocular pressure changes following intravitreal bevacizumab injections in an Indian population

To assess the changes in Intraocular pressure (IOP) after intravitreal bevacizumab therapy.

Prospective, Observational, Tertiary care hospital based study.

95 patients receiving intravitreal bevacizumab, for varying indications, were included.

A study of the change in intraocular pressure of 95 patient eyes receiving intravitreal injection of bevacizumab for varying indications was performed at 4hours, 2 weeks and 6 weeks post injection.

There was a statistically significant increase in IOP 4 hours post injection [p value=.000; 95% confidence limits of 2.07 to-1.11; mean difference of-1.59]. There was no statistical significance in IOP rise at 2 weeks (p= 0.32; 95% confidence limits of-1.13 and 0.18; mean difference of-0.47) or at 6 weeks (p= 1.00; 95% confidence limits of-0.86 to 0.44; mean difference of-0.21). The endpoint IOP in the single injection and multiple injection groups was statistically insignificant (t=-0.32, df = 92, significance value=0.749, 95% confidence interval-1.48 to 1.07).

Although a statistically significant short-term rise in IOP was observed, this increase was clinically insignificant. The IOP reverted towards baseline values on subsequent visits at 2 weeks and 6 weeks post-injection. The number of injections did not have any effect on the IOP change. Clinical significance: Our study evaluated the effect of intravitreal injection of bevacizumab on intraocular pressure in an Indian population and found no clinically significant rise in the same.